

# CHECKMATE PHARMACEUTICALS, INC.

## RESEARCH AND DEVELOPMENT COMMITTEE CHARTER

### I. PURPOSE

The purpose of the Research and Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Checkmate Pharmaceuticals, Inc., a Delaware corporation (the “Company”) is (a) to assist the Company in evaluating research and development issues and decisions and (b) to provide to the Board a detailed perspective on research and development efforts.

The Committee has the authority to undertake the specific responsibilities and duties listed below and will have the authority to undertake such other specific duties as the Board from time to time prescribes. For clarity, absent express delegation by the Board, the Committee will have the general authority to make recommendations to the Board on the matters described herein, but will not have the authority to act on behalf of the Board.

### II. COMPOSITION

The Committee shall be comprised of a minimum of two (2) members of the Board. At least one member of the Committee shall, in the judgment of the Board, have scientific research and development expertise in human therapeutics and the biopharmaceutical industry. Committee members need not be independent directors; provided, however, that the Committee must be composed of at least the same or more independent directors than non-independent directors.

The members of the Committee and its chairperson (“Chair”) shall be appointed by and serve at the discretion of the Board. A member of the Committee shall be automatically removed if the member is no longer a member of the Board.

### III. MEETINGS

The Committee will hold at least one (1) regular meeting per year and additional meetings, as the Chair or Committee deems appropriate. The Committee may from time to time request any officer, employee, consultant or advisor of the Company to meet with the Committee or any consultant or advisors engaged by the Committee.

#### **IV. RESPONSIBILITIES AND DUTIES**

To fulfill its responsibilities and duties, the Committee shall have the power to:

- a. Provide feedback and analysis to Company management regarding, and assist the Board regarding its oversight of, pre-clinical and clinical decision-making through a series of periodic pipeline reviews and in-depth assessments of select project strategies and plans.
- b. Review, evaluate and advise the Board regarding the Company's progress in achieving its short-term and long-term strategic research and development goals and objectives.
- c. Review, evaluate and advise the Board regarding the quality, direction and competitiveness of the Company's research and development programs.
- d. Review and evaluate in-licensing, acquisition and development collaboration opportunities, as requested by Company management or the Board.
- e. Provide recommendations regarding key discovery and development strategies, as requested by the Board from time to time, to align with business needs of the Company.
- f. Provide assistance to the Compensation Committee of the Board and the Board, as requested from time to time, in assessing the capabilities of and evaluating the performance of the Company's key scientific and technical personnel.
- g. Annually, review and reassess the adequacy of this charter and recommend to the Board any amendments or modifications to this charter that the Committee deems appropriate.

The Committee shall have such other responsibilities and authority as may be determined from time to time by the Board. In connection with performing its responsibilities and duties, the Committee is authorized to engage, at the expense of the Company, outside consultants to assist the Committee as necessary or appropriate.

Adopted February 3, 2022